Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer (Q35857230)

10 August 2017

Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer (English)

1 reference

10 August 2017

1 reference

Yoichi Aoki

1

1 reference

10 August 2017

Minoru Watanabe

2

1 reference

10 August 2017

Takayuki Amikura

3

1 reference

10 August 2017

Hiroaki Obata

4

1 reference

10 August 2017

Masayuki Sekine

5

1 reference

10 August 2017

Tetsuro Yahata

6

1 reference

10 August 2017

Kazuyuki Fujita

7

1 reference

10 August 2017

Kenichi Tanaka

8

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

10 August 2017

1 reference

10 August 2017

94

1 reference

10 August 2017

333-339

1 reference

10 August 2017

2

1 reference

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Surgery without radiotherapy for primary treatment of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Operative treatment in stage I endometrial carcinoma with deep myometrial invasion and/or grade 3 tumor surgically limited to the corpus uteri. No recurrence with only primary surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Conservative management of stage I endometrial carcinoma after surgical staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Endometrial carcinoma--relative effectiveness of adjuvant irradiation vs therapy reserved for relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Risk factors and recurrent patterns in Stage I endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Surgical stage I endometrial cancer: predictors of distant failure and death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

High-risk surgical stage 1 endometrial cancer: outcomes with vault brachytherapy alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Is there a survival benefit to adjuvant radiotherapy in high-risk surgical stage I endometrial cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Hematogenous dissemination in corpus cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Pretreatment assessment of prognostic indicators in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.040

10.1016/J.YGYNO.2004.05.040

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference